Abstract
Interleukin (IL)-2 has well-recognized effects on cerebral endothelial cells and, therefore, may mediate disruption of the blood-brain barrier in patients with multiple sclerosis (MS). To evaluate the in vivo relationship of the IL-2 system to blood-brain barrier impairment in MS, levels of IL-2 and soluble IL-2 receptors (sIL-2R) in cerebrospinal fluid (CSF) and serum samples from 50 patients with active MS and 49 controls were correlated with values of the CSF to serum albumin ratio. Intrathecal levels of IL-2 and sIL-2R were significantly higher in MS compared with the control groups and correlated with albumin ratios in MS patients. Intrathecal levels of IL-2 and sIL-2R also correlated with the degree of barrier damage in these patients. It is suggested that intrathecal levels of IL-2 and sIL-2R are related to barrier impairment in MS and may be important in understanding some of the pathological changes of this condition.
Similar content being viewed by others
References
Adachi K, Kumamoto T, Araki S (1989) Interleukin-2 receptor levels indicating relapse in multiple sclerosis. Lancet I:559–560
Adachi K, Kumamoto T, Araki S (1990) Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol 28:687–691
Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW (1988) IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol 141:158–163
Bechard DE, Fowler AA, Grant AJ, Fisher BJ, Sholley M, Merchant RE (1987) Lymphokine-activated killer cells are cytotoxic to human vascular endothelium in vitro. Am Rev Respir Dis 135:A100
Bellamy AS, Calder VL, Feldmann M, Davidson AN (1985) The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes. Clin Exp Immunol 61:248–256
Bernard JT, Ameriso S, Kempf RA, Rosen P, Mitchell MS, Fisher M (1990) Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 40:154–155
Campbell MJ, Gardner MJ (1988) Calculating confidence intervals for some non-parametric analysis. BMJ 296:1454–1456
Convay EM, Bach R, Rosenberg RD, Konigsberg WH (1989) TNF enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 53:231–241
Cotran RS, Pober JS, Gimbrone MA, et al (1987) Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for the vascular leak syndrome. J Immunol 139:1883–1888
Cuzner ML, Hayes GM, Newcombe J, Woodroofe MN (1988) The nature of inflammatory components during demyelination in multiple sclerosis. J Neuroimmunol 20:203–209
Damel NK, Doyle LV (1989) IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers: implications for vascular leak syndrome. J Immunol 142:2660–2669
Damel NK, Doyle CU, Bender JR, Bradley EC (1987) Interleukin-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138:1779–1785
Ellison MD, Povlishock JT, Merchant RE (1987) Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 47:5765–5770
Ellison MD, Krieg RJ, Povlishock JT (1990) Differential central nervous responses following single and multiple recombinant interleukin-2 infusions. J Neuroimmunol 28:249–260
Felgenhauer K (1986) The blood-brain barrier redefined. J Neurol 233:193–194
Gallo P, Piccinno M, Pagni S, et al (1989) Immune activation in multiple sclerosis: study of IL-2, sIL-2R, γ-IFN levels in serum and CSF. J Neurol Sci 92:9–15
Ganrot K, Laurell CB (1974) Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation. Clin Chem 20:571–573
Hallenbeck JM, Dutka AJ, Kochanek PM, et al (1988) Stroke risk factors prepare rat brainstem tissues for a modified local Shwartzman reaction. Stroke 19:863–869
Hicks C, Breit SN, Penny R (1989) The response of human microvascular endothelial cells to biological response modifiers. Immunol Cell Biol 67:271–277
Hicks C, Cooley MA, Panny R (1991) Investigation of interleukin 2 receptors on human endothelial cells. Growth Factors 5:201–208
Hofman FM, Hanwehr RI von, Dinarello CA, et al (1986) Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain. J Immunol 136:3239–3245
Iwasaka K (1990) Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human gliomamass: ultrastructural analysis using a three-dimensional multicellular spheroid model. Arch Jpn Chir 59:39–54
James PB (1989) Multiple sclerosis or blood-brain barrier disease. Lancet I:46
Kermode AG, Thompson AJ, Tofts P, et al (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenic and clinical implications. Brain 113:1477–1489
Kittur SD, Kittur DS, Soncrant TT, Rapoport SI, Tourtellotte WW, Nagel JE, Adler WH (1990) Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol 28:168–173
Koopmans RA, Li DK, Oger JF, Mayo J, Paty DW (1989) The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology 39:959–963
Mier JW, Vachino G, Meer JW van der, et al (1988) Induction of circulating tumour-necrosis factor (TNF-alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426–436
Miltenberg AM, Meijer-Paape ME, Daha MR, Paul LC (1987) Endothelial cell lysis induced by lymphokine-activated human polymorphonuclear cells. Eur J Immunol 17:1383–1386
Peace R, Cheever E (1989) Toxicity and therapeutic efficacy of high dose interleukin-2. J Exp Med 169:161–168
Poser CM, Paty DW, Scheinberg L, et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
Reiber H (1980) The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid. J Neurol 224:89–99
Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration on recombinant interleukin-2. J Immunol 137:1735–1742
Saris SC, Rosenberg SA, Friedman RB, Rubin JT, Barba D, Oldfield EH (1988) Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 69:29–34
Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ (1988) Cytokine activation of vascular endothelium. J Biol Chem 26:5797–5803
Schliep G, Felgenhauer K (1978) Serum-CSF protein gradients, the blood-brain barrier and the local immune response. J Neurol 218:77–96
Sharief MK, Hentges R, Thompson EJ (1991) The relationship of itnerleukin-2 and soluble IL-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis. J Neuroimmunol 32:43–51
Sharief MK, Hentges R, Thompson (1992) Determination of interleukin-2 in cerebrospinal fluid by a sensitive enzyme-linked immunosorbent assay. J Immunol Methods 147:51–56
Tibbling G, Link H, Ohman S (1977) Principles of albumin and IgG analyses in neurological diseases. Establishment of reference values. Scand J Clin Lab Invest 37:285–390
Tourtellotte WW (1985) The cerebrospinal fluid in multiple sclerosis. In: Koetsier JC (ed) Handbook of clinical neurology, vol 3. Demyelinating diseases. Elsevier, Amsterdam, pp 79–130
Trotter JL, Clifford DB, McInnis JE, et al (1989) Correlation of immunological studies and disease progression in chronic progressive MS. Ann Neurol 25:172–178
Vecht CJ, Keohane C, Menon RS, Henzen-Logmans SC, Punt CJ, Stoter G (1990) Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 323:1146–1147
Waldmann TA (1986) The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727–732
Watts RG, Wright JL, Atkinson LL, Merchant RE (1989) Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin-2. Neurosurgery 25:202–208
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sharief, M.K., Hentges, R., Ciardi, M. et al. In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. J Neurol 240, 46–50 (1993). https://doi.org/10.1007/BF00838446
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00838446